

October 22, 2018



Endonovo Therapeutics Provides Update on Liver Study

LOS ANGELES, CA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- [Endonovo Therapeutics, Inc.](#) (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced results performed in a study to determine if Sofpulse® could counteract the effects of nonalcoholic steatohepatitis (NASH) in an animal model.

One to 2 weeks of treatment with Sofpulse®, the non-invasive proprietary device of Endonovo Therapeutics, appeared to counteract several of the disease signs associated with NASH-associated liver damage.

Male mice, 8 weeks old were placed on an MCD diet (methionine-choline deficient diet) for either 7 or 14 days. Feeding mice a diet deficient in methionine and choline is a commonly used mouse model to study the inflammation and hepatic ballooning associated with NASH. To determine if Endonovo's non-invasive medical device could ameliorate the manifestations of a NASH induced diet, mice were exposed to either a proprietary electroceutical therapy system or a sham system during the duration of the MCD diet.

The Hepatocyte ballooning: the hallmark of NASH was observed in all groups, however the animals treated with the medical device for 14 days showed a remarkable lessening of hepatic ballooning – smaller and less ballooning and inflammation.

Alan Collier, CEO of Endonovo Therapeutics, commented, "We are encouraged by the positive results in the mice treated with tPEMF. We believe further studies are necessary, but the 1 to 2 weeks of treatment with Sofpulse® appeared to counteract several of the disease signs attributed with NASH-associated liver damage."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive,

wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com



Source: Endonovo Therapeutics, Inc.